公开(公告)号：US20130295049A1

公开(公告)日：2013-11-07

申请号：US13663741

申请日：2012-10-30

Applicant: ENANTA PHARMACEUTICALS, INC

Inventor： Yao-Ling Qiu ,  Ce Wang ,  Lu Ying ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D403/14 ,  C07D401/14 ,  A61K31/444 ,  A61K31/496 ,  A61K31/506 ,  A61K31/427 ,  A61K31/5377 ,  C07D413/14 ,  C07D451/02 ,  A61K31/46 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/517

CPC classification number: C07D403/14 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/444 ,  A61K31/46 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/695 ,  A61K38/21 ,  A61K45/06 ,  C07D401/14 ,  C07D413/14 ,  C07D451/02 ,  C07F9/65583 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式（I）化合物或其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。